Late-onset Tay-Sachs disease: Adverse effects of medications and implications for treatment

Neurology

Volumn 67, Issue 5, 2006, Pages 875-877

  Shapiro, B E ^a   Hatters Friedman, S ^a   Fernandes Filho, J A ^a   Anthony, K ^a   Natowicz, M R ^b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ANXIOLYTIC AGENT; BACLOFEN; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CENTRAL STIMULANT AGENT; CHLORPROMAZINE; CITALOPRAM; CLONAZEPAM; DIAZEPAM; FLUOXETINE; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LITHIUM; LORAZEPAM; METHYLPHENIDATE; MOOD STABILIZER; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PHENYTOIN; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID;

ADULT; AGED; ARTICLE; BALANCE DISORDER; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; COORDINATION DISORDER; DEPRESSION; DISEASE SEVERITY; DRUG SAFETY; DYSARTHRIA; DYSTONIA; ELECTROCONVULSIVE THERAPY; FEMALE; HEALTH SURVEY; HUMAN; MALE; MENTAL DISEASE; MUSCLE WEAKNESS; NEUROLOGIC DISEASE; PRIORITY JOURNAL; QUESTIONNAIRE; TAY SACHS DISEASE; TREMOR;

ADULT; AGED; ANALGESICS, NON-NARCOTIC; DISEASE PROGRESSION; ELECTROCONVULSIVE THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHOTROPIC DRUGS; RETROSPECTIVE STUDIES; TAY-SACHS DISEASE;

EID: 33748708450     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000233847.72349.b6     Document Type: Article

References (10)

1. M2 gangliosidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular basis of inherited disease. 8th ed. New York: McGraw-Hill, 2001:3827-3876.
2. M2 gangliosidosis resulting from hexosaminidase A deficiency. Ann Neurol 1984;16:14-20.
3. M2 gangliosidosis. Arch Neurol 1976;33:120-130.
4. Rosebush PI, MacQueen GM, Clarke JTR, Callahan JW, Strasberg PM, Mazurek MF. Late Onset Tay Sachs disease presenting as catatonic schizophrenia: diagnostic and treatment issues. J Clin Psychiatry 1995;56:347-353.
5. M2 gangliosidosis. Ann Neurol 1992;31:342-344.
6. Navon R, Baram D. Depletion of cellular B-hexosaminidase by imipramine is prevented by dexamethasone: implications for treating psychotic hexosaminidase A deficient patients. Biochem Biophys Res Commun 1987;48:1098-1103.
7. Lüllman H, Lüllman-Rauch R, Wasserman O. Lipidosis induced by amphiphilic cationic drugs. Biochem Pharmacol 1978;27:1103-1108.
8. Lüllman-Rauch R. Drug-induced lysosomal storage disorders. In: Dingle JT, Jacques PT, Shaw IH, eds. Lysosomes in applied biology and therapeutics. Amsterdam: North Holland, 1979;6:49-130.
9. Honegger UE, Roscher AA, Wiesman UN. Evidence for lysosomotropic action of desipramine in cultured human fibroblasts. J Pharm Exptl Therapeutics 1983;225:436-441.
10. Fischer J, Hein L, Lüllman-Rauch R, von Witzendorff B. Tilorone-induced lysosomal lesions: the bisbasic character of the drug is essential for its potency to cause storage of sulphated glycosaminoglycans. Biochem J 1996;315:369-375.